In the ongoing phase II study, the double immune checkpoint blockade was used—PD-1 inhibition by nivolumab and CTLA-4 inhibition by ipilimumab in platinum-resistant ovarian cancer. This evidence concerns the gene PDCD1 and ovarian carcinoma.